Delivery Order SPE2DX22D0010-SPE2D825FJM36
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $1,120.83. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) with a ceiling value of $16,052.40. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, represents a single fulfillment under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract is classified as a child award, leveraging the company's broader...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for 100 capsules of Vyvanse 30 mg at a ceiling value of $3,913.63. This is a firm fixed-price delivery order with an ultimate completion date of September 26, 2025, executed under a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 5, 2025, for the supply of Vyvanse 70 mg capsules (100-count) with a ceiling value of $3,982.99. This is a firm fixed price delivery order with an ultimate completion date of May 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Vyvanse 70 mg capsules (100-count units) valued at $3,496.33 with a firm fixed price structure. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,253.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $11,625.10 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) at a ceiling value of $1,178.44. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, with performance originating from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a child contract under...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D825FJM36Delivery Order
The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Vyvanse capsules 60mg, with a ceiling value of $7,226.08 and a firm fixed price structure. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's pharmaceutical prime vendor contract with DLA enables the supply of a comprehensive range of medications and medical supplies across multiple therapeutic domains to support defense health operations globally. This specific delivery order for Vyvanse—a controlled prescription medication used primarily for attention deficit hyperactivity disorder treatment—reflects the company's ongoing role in providing specialty pharmaceuticals to federal healthcare programs through its established contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 9/18/25 |